Your browser doesn't support javascript.
loading
One Year Outcomes Following Transplantation with COVID-19-Positive Donor Hearts: A National Database Cohort Study.
Wolfe, Stanley B; Singh, Ruby; Paneitz, Dane C; Rabi, Seyed Alireza; Chukwudi, Chijioke C; Asija, Richa; Michel, Eriberto; Ganapathi, Asvin M; Osho, Asishana A.
Afiliação
  • Wolfe SB; Division of Cardiac Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
  • Singh R; Department of Surgery, Allegheny General Hospital, Pittsburgh, PA 15212, USA.
  • Paneitz DC; Division of Cardiac Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
  • Rabi SA; Division of Cardiac Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
  • Chukwudi CC; Department of Surgery, Johns Hopkins Hospital, Baltimore, MD 21287, USA.
  • Asija R; Division of Cardiac Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
  • Michel E; Division of Cardiac Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
  • Ganapathi AM; Division of Cardiac Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
  • Osho AA; Department of Surgery, Community Memorial Hospital, Ventura, CA 93003, USA.
J Cardiovasc Dev Dis ; 11(2)2024 Jan 31.
Article em En | MEDLINE | ID: mdl-38392260
ABSTRACT
The current understanding of the safety of heart transplantation from COVID-19+ donors is uncertain. Preliminary studies suggest that heart transplants from these donors may be feasible. We analyzed 1-year outcomes in COVID-19+ donor heart recipients using 13 propensity matching. The OPTN database was queried for adult heart transplant recipients between 1 January 2020 and 30 September 2022. COVID-19+ donors were defined as those who tested positive on NATs or antigen tests within 21 days prior to procurement. Multiorgan transplants, retransplants, donors without COVID-19 testing, and recipients allocated under the old heart allocation system were excluded. A total of 7211 heart transplant recipients met the inclusion criteria, including 316 COVID-19+ donor heart recipients. Further, 290 COVID-19+ donor heart recipients were matched to 870 COVID-19- donor heart recipients. Survival was similar between the groups at 30 days (p = 0.46), 6 months (p = 0.17), and 1 year (p = 0.07). Recipients from COVID-19+ donors in the matched cohort were less likely to experience postoperative acute rejection prior to discharge (p = 0.01). National COVID-19+ donor heart usage varied by region region 11 transplanted the most COVID-19+ hearts (15.8%), and region 6 transplanted the fewest (3.2%). Our findings indicate that COVID-19+ heart transplantation can be performed with safe early outcomes. Further analyses are needed to determine if long-term outcomes are equivalent between groups.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Cardiovasc Dev Dis Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Cardiovasc Dev Dis Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos